Skip to content
Screener

Omeros OMER Retained Earnings

Retained Earnings at other companies

Immunome logo
ImmunomeIMNM
-$782M-40.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$691.48M-42.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$3.81B-4.3%
Annexon logo
AnnexonANNX
-$961.53M-25.7%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$750.86M-12.4%
Vor Biopharma logo
Vor BiopharmaVOR
-$1.37B-180%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$958.97M+245%
P/S10.7×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Omeros’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:07 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001437749-26-016720
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 10)
Shareholders’ deficit:
Preferred stock, par value $0.01 per share, 20,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025.
Common stock, par value $0.01 per share, 150,000,000 shares authorized at March 31, 2026 and December 31, 2025; 71,998,632 and 71,670,791 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively.720716
Additional paid-in capital793,581791,748
Accumulated deficit(857,635)(913,695)
Total shareholders’ deficit(63,334)(121,231)
Total liabilities and shareholders’ deficit$286,173$325,632

Document

FAQ

What is Omeros's retained earnings?
Omeros (OMER) reported retained earnings of -$857.64M in Q1 2026.
How has Omeros's retained earnings changed year-over-year?
Omeros's retained earnings increased by 9.1% year-over-year, from -$943.81M to -$857.64M.
What is the long-term trend for Omeros's retained earnings?
Over 5 years (2020 to 2025), Omeros's retained earnings has grown at a 0.9% compound annual growth rate (CAGR), from -$872.67M to -$913.7M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Omeros's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude